FGFR4-IN-5

• CAT Number: I045448
• CAS Number: 1628793-01-0
• Molecular Formula: C23H23Cl2N5O5
• Molecular Weight: 520.37
• Purity: ≥95%
• Synonyms: N-[(3R,4S)-4-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-8-methyl-7-oxopyrido[2,3-d]pyrimidin-2-yl]amino]oxolan-3-yl]prop-2-enamide
• InChI: InChI=1S/C23H23Cl2N5O5/c1-5-17(31)27-13-9-35-10-14(13)28-23-26-8-11-6-12(22(32)30(2)21(11)29-23)18-19(24)15(33-3)7-16(34-4)20(18)25/h5-8,13-14H,1,9-10H2,2-4H3,(H,27,31)(H,26,28,29)/t13-,14+/m0/s1
• InChIKey: ZIJVLVUPDVUSMA-UONOGXRCSA-N
• SMILES: CN1C2=NC(=NC=C2C=C(C1=O)C3=C(C(=CC(=C3Cl)OC)OC)Cl)NC4COCC4NC(=O)C=C

FGFR4-IN-5 (Cat No.: I045448) is a potent, selective inhibitor of fibroblast growth factor receptor 4 (FGFR4), a receptor tyrosine kinase involved in regulating bile acid metabolism, cell proliferation, and cancer progression. By targeting FGFR4, it blocks receptor autophosphorylation and downstream signaling pathways such as MAPK and PI3K/Akt, leading to reduced tumor cell growth. FGFR4-IN-5 is primarily investigated in hepatocellular carcinoma (HCC) and other FGFR4-driven cancers. It serves as a valuable research tool for studying FGFR4 biology and developing targeted cancer therapies with improved specificity.

Reference

[1]. Haibo Liu, et al. Discovery of Selective, Covalent FGFR4 Inhibitors with Antitumor Activity in Models of Hepatocellular Carcinoma. ACS Med Chem Lett. 2020 Mar 6;11(10):1899-1904.
[Content Brief]